.svg)
Members of CNG and CNG as a whole contribute to multiple aspects for society locally, nationally and internationally. We work to disseminate our knowledge gained from research.
The cerebrovascular team have developed a programme to educate stroke-patients and their relatives after the fact, in evidence based “Stroke school”. Annually, we contribute with lectures during the national “Brainweek”, in addition to numerous invited lectures nationally for other colleagues and ideal patient-interest organisations. We aim to improve the awareness of the common diseases in CNS and how to prevent and/or treat them.
We work with national and international consortia, steering committees, and reference groups. During 2012-2022 we’ve had members serving as expert member for the Scientific Advisory Group of EMA; board member for the European Congress on treatment and research in MS (ECTRIMS), board member for the Norwegian Multiple Sclerosis Competence center; contributed to national guideline for treatment of multiple sclerosis as writing member in working group appointed by Norwegian Directorate of Health (2017/2022); Associate member of National Expert Panel for People with serious Life threatening Disease; in the working groups of the European Academy of Neurology for headache and migraine treatment; several positions in the International Headache Society; board member and chairman of the board for Nansen Neuroscience Network, board member in the Norwegian Stroke association (NSO); board member of the Kavli foundation, and more.
Through this we’ve contributed to the development of national and international guidelines in the treatment of our fields of interest. Further, we participate in the continuous upkeep of Norwegian guidelines for clinical neurology (“Nevro-NEL”), as well.
A major focus has been the aim to improve early diagnosis and contribute to implementation of disease-modifying treatments for major diseases leading to dementia, with a focus on Alzheimer’s disease (AD), and AD interactions with small vessel disease. During the 2012-2022 period we have established and led a large national network, with both a research focus as well as a focus on establishing competences for state-of-the-art pre-dementia disease diagnostics at the other national DDI centers (as stated in the project plan). This process has been supported by the parallel participation in European networks developing and establishing new biomarkers, routines for sample handling, MRI protocols etc.
As part of this, the group has developed expertise in innovation over several years in collaboration with Biotech company PreDiagnostics, which continues to work with intellectual properties developed in the field of cognitive impairment while the research group pursues further innovations.
With our large catchment area, we have and continue to contribute in steering committees, and with patient inclusion in numerous clinical trials in both national and international setting (OVERLORD-MS, SMART-MS, RAM-MS, ENSEMBLE, STATICH, NOR-TEST, TWIST, NO-ALS, NOPARK, LAST-long, ELAN, Cand-Mig, AneED, and more).
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
See all
CNG currently has 12 PhD students among its members. Since 2012, members of CNG have supervised 28 PhD students as main supervisor, of which CNG has hosted the education of 21 (see below). In addition, over 20 medical student projects and two Master’s degrees were completed under our supervision.